Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. - Wikidata - awgldk - TriplyDB

Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure.

Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure.

http://www.wikidata.org/entity/Q43136870

about

Beyond the Limits: Clinical Utility of Novel Cardiac Biomarkers Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1 Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study.Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.Optimizing triage and hospitalization in adult general medical emergency patients: the triage project Plasma midregional pro-adrenomedullin improves prediction of functional outcome in ischemic stroke.Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction.Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner.Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models.Multiple biomarkers for risk prediction in chronic heart failure.Impact of Exhaled Breath Acetone in the Prognosis of Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). One Year of Clinical Follow-up Cardiorenal biomarkers in acute heart failure.Adrenomedullin for Risk Stratification of Emergency Patients With Nonspecific Complaints: An Interventional Multicenter Pilot Study.Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.Novel biomarkers in chronic heart failure.Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker?Heart failure biomarkers.The use of biomarkers in the patient with heart failure.Novel biomarkers for heart failure.BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure.Incremental predictive value of natriuretic peptides for prognosis in the chronic stable heart failure population: a systematic review.Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock.The Current and Potential Clinical Relevance of Heart Failure Biomarkers.New Targets in the Drug Treatment of Heart Failure.Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial.Stable State Proadrenomedullin Level in COPD Patients: A Validation Study.Adrenomedullin Is Associated With Surgical Trauma and Impaired Renal Function in Vascular Surgery Patients.Less increase of copeptin and MR-proADM due to intervention with selenium and coenzyme Q10 combined: Results from a 4-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens.Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure.Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction.The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure.Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach.Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.The prognostic value of MR-proadrenomedullin in patients with acute coronary syndrome complicated by cardiogenic shock.Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.Serum copeptin and midregion proadrenomedullin (MR-proADM) after an ultramarathon.

P2860

Q26778588-D8B2E436-58DF-461C-A9EF-A1C2B9B9DA48 Q28743491-8C915FB1-0028-4E17-B212-9C7826C2D11E Q33869378-140EC8FD-94F5-428A-8BB4-4EBC3DB5E311 Q34241396-8FB891D5-2429-4AB6-AD11-1C909D01DEFA Q34791783-6206A773-584B-4CDC-822A-ADD3365680FC Q34873180-CC1FAD1C-A44C-4A3A-8136-C7CE00EC9365 Q35003806-30D07DEC-B100-4F34-9BC5-835D2DCD90F6 Q35668366-FBBA86E5-E8C6-4F0F-AC28-D5307538099D Q35952350-952249AF-7DFF-4288-A7D7-54FE36689456 Q36070049-5147D3CD-204E-4125-B143-F660911B4FAC Q36234809-9AA21DC8-05EA-4356-B1CD-85615C63316C Q36313675-91D117B7-DB26-4DC9-B9FF-B23700D9E9CF Q36445043-8D2E7904-5526-4219-9E3E-E67450F7A450 Q37970489-70487E38-285F-47F4-A11C-3D6CF5A9FD7A Q37997237-F945B264-8DFB-4695-A7CD-C60869948DA5 Q38021707-995EBFF5-8675-484D-872D-38EAE8888509 Q38100647-0D8F47A1-E9B7-4C22-9FA0-403230CF3607 Q38104269-928C8456-E2FB-48E8-B849-E30882519CB6 Q38131790-3AFB611B-EC8B-4F90-8D86-6ED1AA1C0311 Q38225445-97AA56D2-BD6C-4CA0-BAE5-85EA05F60E6C Q38239624-B39F00A4-D812-4D6F-91D5-7BD7EC3A7909 Q38382864-F4F3B18A-29FF-4DEA-B2BE-4731F3915557 Q38568205-CB39F847-2F34-4ED8-9061-5DEDAE184561 Q38667210-52820644-F814-46BE-A041-FC1B41ED8A2B Q39014581-E061C0AD-F428-4E33-9CDE-95B4EF10E730 Q39158752-D33453E9-6A72-4A63-AD39-494B68E45F1E Q40362800-51BAD3E3-93E4-4B83-B84A-A6E9CFF504EA Q41054976-C5946F76-E00B-41EC-BFA1-437035AC6C98 Q41993082-26757C11-F345-4AB5-9BB9-9FA1145175A6 Q44466897-66016C5F-8C26-47AD-913A-6DB4A61B90F8 Q46306260-63556E0F-B2DE-4518-A2B0-342E5B3AE2B6 Q47689172-7A051A64-DB7A-4FF5-B315-EED68B5551E4 Q47760332-5CAD47BA-B7FC-4D74-ACF8-E70F55932611 Q48156451-7CD2066A-3D1E-4209-AEDF-68042EC3071C Q48232718-75330AD0-3BEF-492D-A79F-B6759BE0F60B Q48762611-B587DEB2-A78B-40EA-A30A-8A7D141ECEEE Q50949002-9035E003-2ADE-4A2E-85F6-582992F8DF70 Q51359233-2AB70C3C-13E9-4B51-8833-02CC013E5907 Q52687475-A662EE33-1770-4C4C-B729-AF5FC52FAD4F Q54365449-C2DDC92A-C65E-46B4-9191-636676B2C6D4

P2860

Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure.

http://www.wikidata.org/entity/Q43136870

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Mid-regional pro-adrenomedulli ...... ts with chronic heart failure.

@en

Mid-regional pro-adrenomedulli ...... ts with chronic heart failure.

@nl

type

label

Mid-regional pro-adrenomedulli ...... ts with chronic heart failure.

@en

Mid-regional pro-adrenomedulli ...... ts with chronic heart failure.

@nl

prefLabel

Mid-regional pro-adrenomedulli ...... ts with chronic heart failure.

@en

Mid-regional pro-adrenomedulli ...... ts with chronic heart failure.

@nl

P1433

Q43136870-111CD84F-8C48-4438-8E6F-566B8F18E96B

P1476

Q43136870-1B21173B-4C31-41E6-A4CA-F3DA04B60124

P2093

Q43136870-205CF8AB-AB95-4874-8AA8-4B505B4BFBFE

Q43136870-64D6680A-39D1-45B2-9290-6A8073998D83

Q43136870-772D400B-38EB-4472-A321-297F85E00A16

Q43136870-85C4D1AF-BC92-4CDB-83CA-1AE39494B450

Q43136870-963B8AFA-41EC-4A48-B62F-114061B73B57

Q43136870-9B06A81B-5700-4B00-BC93-0CCBA6F99FA6

Q43136870-A9ACD927-0E0E-4698-91EB-11E85A4C0F41

Q43136870-B0100BBE-C7FC-4361-8EED-F749B7237169

Q43136870-C4C8495B-4D32-4864-B70E-FA6B5C6B7F50

Q43136870-E731C88E-CD0A-461B-B71B-AC9B6DBF97CB

P304

Q43136870-CD6DFC4D-CA74-4A4B-88B7-00342E6C1E1C

P31

Q43136870-D6F8878E-9343-446C-9ED0-9D2902A1FF68

P356

Q43136870-175EFCFC-224B-4F14-A276-1F66495E2C08

P433

Q43136870-9B620D9F-F4E3-4230-82FF-6B2BB0C6431E

P478

Q43136870-D5B29397-74AE-469E-AE02-37C0AC3174EA

P50

Q43136870-3D4BAFCA-B8E0-4EBE-BBF5-9F75AC52F934

Q43136870-3ECA4336-54EB-457B-863B-E9E9437FBD24

Q43136870-86022FD3-EABE-4727-B763-AD8AF3540634

Q43136870-A6086B92-23D1-45B9-B203-9E9BF029ECA8

Q43136870-E08F7599-2BE7-41A5-88A5-680FD4B40982

P577

Q43136870-BCC382A4-8EB7-49C1-A54F-9BC6E2A8E6AA

P698

Q43136870-6133D915-0A03-42AD-B69E-411951F1E51B

P356

P1433

European Journal of Heart Failure

P1476

Mid-regional pro-adrenomedulli ...... ts with chronic heart failure.

@en

P2093

Andreas Bergmann

http://www.w3.org/2001/XMLSchema#string

Corrado Vassanelli

http://www.w3.org/2001/XMLSchema#string

Dimitrios Kremastinos

http://www.w3.org/2001/XMLSchema#string

Gerasimos S Filippatos

http://www.w3.org/2001/XMLSchema#string

Jana Papassotiriou

http://www.w3.org/2001/XMLSchema#string

Joachim Struck

http://www.w3.org/2001/XMLSchema#string

Mariantonietta Cicoira

http://www.w3.org/2001/XMLSchema#string

Nils G Morgenthaler

http://www.w3.org/2001/XMLSchema#string

Piotr Rozentryt

http://www.w3.org/2001/XMLSchema#string

Wolfram Doehner

http://www.w3.org/2001/XMLSchema#string

P304

484-491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURJHF/HFQ031

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Piotr Ponikowski

Stefan D. Anker

Ewa A Jankowska

Stephan von Haehling

Waldemar Banasiak

P577

2010-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20215339

http://www.w3.org/2001/XMLSchema#string